IRD
Opus Genetics Inc.
Company Overview
| Mkt Cap | $124.01M | Price | $2.36 |
| Volume | 333.86K | Change | -3.28% |
| P/E Ratio | -2.2 | Open | $2.43 |
| Revenue | $11.0M | Prev Close | $2.44 |
| Net Income | $-57.5M | 52W Range | $0.65 - $2.59 |
| Div Yield | N/A | Target | $7.63 |
| Overall | 45 | Value | 40 |
| Quality | 31 | Technical | 66 |
No chart data available
About Opus Genetics Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Latest News
Kepler Capital Reaffirms Their Buy Rating on Viridien (0RI9)
HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks
Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
Cathie Wood Doubles Down on Bitcoin, Cuts Exposure Across Tech and Genomics
Rocket Doctor AI Partners to Launch AI-Powered Clinical Support in Alberta
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IRD | $2.36 | -3.3% | 333.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |